These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38483304)

  • 1. Healthcare Costs of Irritable Bowel Syndrome and Irritable Bowel Syndrome Subtypes in the United States.
    Shin A; Xu H
    Am J Gastroenterol; 2024 Aug; 119(8):1571-1579. PubMed ID: 38483304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
    Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
    J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured Population.
    Buono JL; Mathur K; Averitt AJ; Andrae DA
    J Manag Care Spec Pharm; 2017 Apr; 23(4):453-460. PubMed ID: 28345443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A case-control comparison of direct healthcare-provider medical costs of chronic idiopathic constipation and irritable bowel syndrome with constipation in a community-based cohort.
    Herrick LM; Spalding WM; Saito YA; Moriarty J; Schleck C
    J Med Econ; 2017 Mar; 20(3):273-279. PubMed ID: 27783533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic burden of irritable bowel syndrome in China.
    Zhang F; Xiang W; Li CY; Li SC
    World J Gastroenterol; 2016 Dec; 22(47):10450-10460. PubMed ID: 28058026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation.
    Nellesen D; Yee K; Chawla A; Lewis BE; Carson RT
    J Manag Care Pharm; 2013; 19(9):755-64. PubMed ID: 24156644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries.
    Tack J; Stanghellini V; Mearin F; Yiannakou Y; Layer P; Coffin B; Simren M; Mackinnon J; Wiseman G; Marciniak A;
    BMC Gastroenterol; 2019 May; 19(1):69. PubMed ID: 31064345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective and prospective 12-month observational study of the socioeconomic burden of moderate to severe irritable bowel syndrome with constipation in Spain.
    Mearin F; Caballero AM; Serra J; Brotons C; Tantiñà A; Fort E; Martínez-Cerezo FJ; Perelló A; Sánchez-Antolín G; Rey E; Angós Musgo R; Berdier R; Gómez-Rodríguez B; Clavé P; García-Alonso M; Torán-Monserrat P; Tack J
    Gastroenterol Hepatol; 2019 Mar; 42(3):141-149. PubMed ID: 30612850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variation in Care for Patients with Irritable Bowel Syndrome in the United States.
    Lacy BE; Patel H; Guérin A; Dea K; Scopel JL; Alaghband R; Wu EQ; Mody R
    PLoS One; 2016; 11(4):e0154258. PubMed ID: 27116612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Healthcare spending and utilization for pediatric Irritable Bowel Syndrome in a commercially insured population.
    Beinvogl B; Palmer N; Kohane I; Nurko S
    Neurogastroenterol Motil; 2021 Nov; 33(11):e14147. PubMed ID: 33818857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The economic burden of treatment failure amongst patients with irritable bowel syndrome with constipation or chronic constipation: a retrospective analysis of a Medicaid population.
    Guerin A; Carson RT; Lewis B; Yin D; Kaminsky M; Wu E
    J Med Econ; 2014 Aug; 17(8):577-86. PubMed ID: 24811855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Costs of health care for irritable bowel syndrome, chronic constipation, functional diarrhoea and functional abdominal pain.
    Nyrop KA; Palsson OS; Levy RL; Von Korff M; Feld AD; Turner MJ; Whitehead WE
    Aliment Pharmacol Ther; 2007 Jul; 26(2):237-48. PubMed ID: 17593069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-patient discharge rates for the irritable bowel syndrome - an analysis of national trends in the United States from 1997 to 2010.
    Sethi S; Wadhwa V; LeClair J; Mikami S; Park R; Jones M; Sethi N; Brown A; Lembo A
    Aliment Pharmacol Ther; 2013 Dec; 38(11-12):1338-46. PubMed ID: 24206371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irritable bowel symptoms, use of healthcare, costs, sickness and disability pension benefits: A long-term population-based study.
    Poulsen CH; Eplov LF; Hjorthøj C; Hastrup LH; Eliasen M; Dantoft TM; Schröder A; Jørgensen T
    Scand J Public Health; 2019 Dec; 47(8):867-875. PubMed ID: 29762084
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of medical costs generated by IBS patients in primary and secondary care in the Netherlands.
    Flik CE; Laan W; Smout AJ; Weusten BL; de Wit NJ
    BMC Gastroenterol; 2015 Nov; 15():168. PubMed ID: 26612205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive assessment of patients with irritable bowel syndrome with constipation and chronic idiopathic constipation using deterministically linked administrative claims and patient-reported data: the Chronic Constipation and IBS-C Treatment and Outcomes Real-World Research Platform (CONTOR).
    Taylor DCA; Abel JL; Martin C; Doshi JA; Essoi B; Korrer S; Reasner DS; Carson RT; Hunter AG
    J Med Econ; 2020 Oct; 23(10):1072-1083. PubMed ID: 32696684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How does comorbidity affect cost of health care in patients with irritable bowel syndrome? A cohort study in general practice.
    Johansson PA; Farup PG; Bracco A; Vandvik PO
    BMC Gastroenterol; 2010 Mar; 10():31. PubMed ID: 20233451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic burden of inadequate symptom control among US commercially insured patients with irritable bowel syndrome with diarrhea.
    Buono JL; Mathur K; Averitt AJ; Andrae DA
    J Med Econ; 2017 Apr; 20(4):353-362. PubMed ID: 27919177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Costs of irritable bowel syndrome in the UK and US.
    Maxion-Bergemann S; Thielecke F; Abel F; Bergemann R
    Pharmacoeconomics; 2006; 24(1):21-37. PubMed ID: 16445300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct healthcare costs of Rome IV or Rome III-defined irritable bowel syndrome in the United Kingdom.
    Goodoory VC; Ng CE; Black CJ; Ford AC
    Aliment Pharmacol Ther; 2022 Jul; 56(1):110-120. PubMed ID: 35491477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.